Biology subjects

Agami, R.

Publications and source records attributed to Agami, R..

4 recordsLinked to original sources

bioRxiv2025

Identification of RNA binding proteins that mediate a quality control mechanism of splicing

Accurate splicing, which involves the controlled removal of non-coding sequences (introns) from precursor messenger RNAs (pre-mRNAs), is essential for producing correct mature mRNAs that encode functional proteins. Within pre-mRNAs, latent splice sites (LSSs) resemble proper splice sites but are usually not used because their activation can introduce in-frame STOP codons. The nuclear suppression of splicing (SOS) mechanism prevents the use of LSSs. Although the SOS mechanism is not fully understood, recent studies have identified initiator-tRNA and the NCL protein as key components. To discover additional regulators, we performed a genetic screen targeting RNA-binding proteins (RBPs) with an siRNA library and a luminescence reporter for latent splice site activation. This identified five RBPs -- ALYREF (THOC4), PPIE, DDX41, DHX38, and HNRNPA2B1 -- whose knockdown significantly increased LSS usage in the reporter. RNA-Seq analysis after knocking down each of these RBPs confirmed these results, showing widespread LSS activation in hundreds of mRNAs. Among these, we focused on ALYREF, a conserved protein involved in mRNA export and splicing. Using fPAR-CLIP, we found that U5 snRNA is ALYREFs main binding partner. Overexpressing ALYREF deletion mutants activated latent splicing, and affinity purification confirmed its interaction with U5 snRNA. These mutants exhibited different binding properties, highlighting the importance of specific structural elements within ALYREF in SOS regulation. Our findings reveal that nuclear RBPs play a key role in suppressing LSS activation and suggest that ALYREF has a novel role in maintaining splicing accuracy within the spliceosome, advancing our understanding of the SOS mechanism.

genomics↗

bioRxiv2025

MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation

Profiling antigens presented on MHC class I molecules on the cell surface is essential to identify candidate antigens for targeted and personalized immunotherapies. However, mass spectrometry-based immunopeptidomics has traditionally been limited by high input requirements, extensive sample manipulation, and expensive reagents. To overcome these challenges, we developed MHC1-TIP: a scalable, single-tube and cost-effective workflow to enable robust MHC-I ligandome recovery from cell lines, patient-derived organoids, and sub-milligram amounts of clinical tissues. Moreover, MHC1-TIP also preserves compatibility with additional omics profiling technologies and we demonstrate its capacity for quantitative and multimodal profiling of the proteome and immunopeptidome from the same sample to enable integrated analyses of protein expression and antigen presentation. Application of MHC1-TIP to primary renal cell carcinoma fragments revealed extensive intratumoral heterogeneity in antigen presentation that was poorly correlated with source protein expression. MHC1-TIP represents a broadly applicable and sensitive approach for low-input, multimodal immunopeptidomics with clinical and translational relevance.

systems biology↗

bioRxiv2025

Upstream open reading frame translation enhances immunogenic peptide presentation in mitotically arrested cancer cells

Mitosis is a critical phase of the cell cycle and a vulnerable point where cancer cells can be effectively disrupted, leading to cell death and inhibition of tumor growth. However, challenges such as drug resistance remain significant in clinical applications. During mitosis, mRNA translation is generally downregulated, while non-canonical translation of specific transcripts proceeds. Here, we demonstrate that mitotic cancer cells redistribute ribosomes toward the 5 untranslated region (5 UTR) and the start of the coding sequence (CDS), enhancing the translation of thousands of upstream open reading frames (uORFs) and upstream overlapping open reading frames (uoORFs). This mitotic induction of uORF/uoORF enriches the presentation of immunopeptides at the surface of cancer cells following treatment with mitotic inhibitors. Functional assays indicate the potential of such neoepitopes to provoke cancer-cell killing by T cells. Altogether, our findings highlight the therapeutic potential of targeting uORF/uoORF-derived neoepitopes in combination with mitotic inhibitors to enhance immune recognition and tumor cell elimination.

cancer biology↗

bioRxiv2023

Gene and protein sequence features augment HLA class I ligand predictions

The sensitivity of malignant tissues to T cell-based cancer immunotherapies is dependent on the presence of targetable HLA class I ligands on the tumor cell surface. Peptide intrinsic factors, such as HLA class I affinity, likelihood of proteasomal processing, and transport into the ER lumen have all been established as determinants of HLA ligand presentation. However, the role of sequence features at the gene and protein level as determinants of epitope presentation has not been systematically evaluated. To address this, we performed HLA ligandome mass spectrometry on patient-derived melanoma lines and used this data-set to evaluate the contribution of 7,124 gene and protein sequence features to HLA sampling. This analysis reveals that a number of predicted modifiers of mRNA and protein abundance and turn-over, including predicted mRNA methylation and protein ubiquitination sites, inform on the presence of HLA ligands. Importantly, integration of gene and protein sequence features into a machine learning approach augments HLA ligand predictions to a comparable degree as predictive models that include experimental measures of gene expression. Our study highlights the value of gene and protein features to HLA ligand predictions.

immunology↗